July 08, 2025

Training Staff for the Presbyopia Journey

Presbyopia isn’t new—but the way we treat it has changed dramatically. As we continue to embrace these advancements, let’s also commit to the one constant that always makes a difference: a well-trained, well-informed team.

Ophthalmic Professional

July 01, 2025

Director of Clinical Resources Group Announces Report on Ocular Risks of Glucagon-Like Peptide-1 Agonists

During the AOA’s 2025 House of Delegates meeting, director of the AOA’s clinical resources group, Andrew Morgenstern, OD, announced the report, “Glucagon-like Peptide-1 Receptor Agonists and Ocular Health: Guidance for Optometric Practice.”

Optometric Management

June 30, 2025

A Second Glance

An international research team challenges the main hypothesis regarding the evolution of human eye appearance

The Ophthalmologist

June 27, 2025

Weight Loss Drugs, Heavier Implications

New guidance positions GLP-1 and GLP-1/GIP therapies as frontline options for long-term weight management—with profound implications for cardiovascular outcomes, access equity, and chronic disease care.

Conexiant

June 27, 2025

New Guidance Targets Risk-Based Diabetes Care

A new review outlines updated strategies for diagnosing and managing type 2 diabetes, recommending earlier use of SGLT2 inhibitors and GLP-1 receptor agonists in patients with cardiovascular or kidney conditions.

Conexiant

June 25, 2025

Number of Cancer Survivors in the United States Reaches 18.6 Million and Projected to Exceed 22 Million by 2035

The number of people living with a history of cancer in the United States is estimated at 18.6 million as of January 1, 2025, and projected to exceed 22 million by 2035, according to a new report, Can...

The ASCO Post

June 24, 2025

AAP Updates Adolescent Contraceptive Guidance

The American Academy of Pediatrics updates contraception guidelines for adolescents, emphasizing access, confidentiality, equity, and person-centered counseling.

Conexiant

June 13, 2025

Weight Loss Drugs Show Promise for Heart Failure

ACC statement highlights semaglutide and tirzepatide as therapies associated with improved symptoms and functional capacity in patients with heart failure with preserved ejection fraction and obesity.

Conexiant

October 29, 2024

New Data Challenges Pediatric Sinusitis Treatment Guidelines

A JAMA review revealed that only 26% of pediatric ABRS patients treated with placebo required subsequent antibiotic therapy, prompting questions about current guidelines recommending first-line antibiotic use in children with sinusitis.

Conexiant